Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Total Liabilities (2020 - 2025)

Historic Total Liabilities for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $27.6 million.

  • HCW Biologics' Total Liabilities fell 2456.7% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 2456.7%. This contributed to the annual value of $37.0 million for FY2024, which is 14586.03% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Total Liabilities is $27.6 million, which was down 2456.7% from $29.0 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' Total Liabilities ranged from a high of $37.0 million in Q4 2024 and a low of $1.2 million during Q2 2022
  • Its 5-year average for Total Liabilities is $18.3 million, with a median of $13.4 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 9657.32% in 2022, then soared by 77672.2% in 2023.
  • Quarter analysis of 5 years shows HCW Biologics' Total Liabilities stood at $2.3 million in 2021, then soared by 304.06% to $9.4 million in 2022, then surged by 60.46% to $15.1 million in 2023, then soared by 145.86% to $37.0 million in 2024, then dropped by 25.55% to $27.6 million in 2025.
  • Its Total Liabilities stands at $27.6 million for Q3 2025, versus $29.0 million for Q2 2025 and $34.8 million for Q1 2025.